In the context of new treatments, it has been demonstrated that the silencing of TRIB3 using the molecular inhibitor hesperidin in HNSC induced ferroptosis and promoted cell death, suggesting that this gene could be a target for an innovative therapeutic strategy for HNSCC. Here, TRIB3 is linked to head and neck squamous cell carcinoma.